Advertisement
Research Article| Volume 9, ISSUE 1, P1-6, March 1989

Lowering Blood Cholesterol to Reduce Coronary Heart Disease Risk

  • Reagan H. Bradford
    Correspondence
    Corresponding author: Lipid Metabolism-Atherogenesis Branch National Heart, Lung and Blood Institute Federal Building, Room 401 7550 Wisconsin Avenue Bethesda, Maryland 20892.
    Affiliations
    Special Expert, Lipid Metabolism-Atherogenesis Branch, Division of Heart and Vascular Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland

    Director, Oklahoma Lipid Research Clinic, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma
    Search for articles by this author
  • Basil M. Rifkind
    Affiliations
    Chief, Lipid Metabolism-Atherogenesis Branch, Division of Heart and Vascular Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)30637-1
Lowering Blood Cholesterol to Reduce Coronary Heart Disease Risk
Previous ArticlePreface
Next ArticleThe National Cholesterol Education Program
      This paper is only available as a PDF. To read, Please Download here.
      Key recent findings provide definitive evidence that lowering blood cholesterol in humans reduces coronary heart disease risk. These research advances serve as the basis for national guidelines concerning the medical and public health implications of lowering blood cholesterol to prevent heart disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Blankenhorn D.H.
        • Nesim S.A.
        • Johnson R.L.
        • et al.
        Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
        JAMA. 1987; 257: 3233
        • Brown M.S.
        • Goldstein J.L.
        A receptor-mediated pathway for cholesterol homeostasis.
        Science. 1986; 232: 34
        • Frick M.H.
        • Elo O.
        • Haapa K.
        • et al.
        Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.
        N Engl J Med. 1987; 317: 1237
        • Goldstein J.
        • Brown M.
        Genetics and cardiovascular disease.
        in: Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. W.B. Saunders, Philadelphia1988: 1617
        • Kannel W.B.
        • Neaton J.D.
        • Wentworth D.
        • et al.
        Overall and CHD mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT.
        Am Heart J. 1986; 112: 825
      6. Coronary heart disease in seven countries.
        in: Keyes A. Circulation. 41. 1970 (Suppl 1)
        • Levy R.I.
        • Brensike J.F.
        • Epstein S.E.
        • et al.
        The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: Results of the NHLBI Type II Coronary Intervention Study.
        Circulation. 1984; 69: 325
        • Lipid Research Clinics Program
        The Lipid Research Clinics Coronary Primary Prevention Trial Results: I Reduction in incidence of coronary heart disease.
        JAMA. 1984; 231: 360
        • Lipid Research Clinics Program
        The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.
        JAMA. 1984; 251: 365
        • Manninen V.
        • Elo M.O.
        • Frick H.
        • et al.
        Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
        JAMA. 1988; 260: 641
        • NIH Consensus Development Conference
        Lowering blood cholesterol to prevent heart disease.
        JAMA. 1985; 253: 2080
        • Pooling Project Research Group
        Relationship of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: Final report of the pooling project.
        J Chronic Dis. 1978; 31: 201
        • Report of the National Cholesterol Education Expert Panel on Detection
        Evaluation and Treatment of High Blood Cholesterol in Adults.
        Arch Intern Med. 1988; 148: 36
        • Tyroler H.A.
        Review of lipid-lowering clinical trials in relation to observational studies.
        Circulation. 1987; 76: 515
        • Yano K.
        • Reed S.M.
        • McGee D.L.
        Ten-year incidence of coronary heart disease in the Honolulu heart program. Relationship to biologic and lifestyle characteristics.
        Am J Epidemiol. 1984; 119: 653

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30637-1

      Copyright

      © 1989 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX